NCT06692465View on ClinicalTrials.gov

To Evaluate the Efficacy and Safety of GT20029 Solution in the Treatment of Androgenetic Alopecia (AGA) in Chinese Adult Males

PHASE2CompletedINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

April 13, 2023

Primary Completion Date

December 14, 2023

Study Completion Date

June 30, 2024

Conditions
AlopeciaMale Pattern Hair Loss
Interventions
DRUG

GT20029 Tincture

5mg (0.5%) and 10mg (1%) one single dose per day (QD) treatment over 12 weeks period; 5mg (0.5%) and 10mg (1%) twice per week (BIW) treatment, on every Monday and Thursday over 12 weeks period

DRUG

GT20029 matching placebo

5mg (0.5%) and 10mg (1%) matching placebo one single dose per day (QD) treatment over 12 weeks period; 5mg (0.5%) and 10mg (1%) matching placebo twice per week (BIW) treatment, on every Monday and Thursday over 12 weeks period

Trial Locations (1)

Unknown

Dermatology department, Huashan Hospital, Fudan University, Shanghai

All Listed Sponsors
collaborator

Suzhou Koshine Biomedica, Inc.

INDUSTRY

lead

Suzhou Kintor Pharmaceutical Inc,

INDUSTRY